Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy

Aim: Proprotein convertase subtilisin/kexin type 9 (PCSK9) degrades the low-density lipoprotein (LDL) receptor, leading to hypercholesterolemia and cardiovascular risk. Treatment with a statin leads to a compensatory increase in circulating PCSK9 level. Anagliptin, a dipeptidyl peptidase-4 (DPP-4) i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of Atherosclerosis and Thrombosis 2022/01/01, Vol.29(1), pp.24-37
Hauptverfasser:	Furuhashi, Masato, Sakuma, Ichiro, Morimoto, Takeshi, Higashiura, Yukimura, Sakai, Akiko, Matsumoto, Megumi, Sakuma, Mio, Shimabukuro, Michio, Nomiyama, Takashi, Arasaki, Osamu, Node, Koichi, Ueda, Shinichiro
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Anagliptin Cholesterol, HDL - blood Cholesterol, LDL - blood Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Dipeptidyl peptidase-4 inhibitor Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Female Glycated Hemoglobin A - metabolism Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hypercholesterolemia - blood Hypercholesterolemia - complications Hypercholesterolemia - drug therapy Male Middle Aged Original Platelet Count Proprotein Convertase 9 - blood Proprotein convertase subtilisin/kexin Pyrimidines - therapeutic use Sitagliptin Sitagliptin Phosphate - therapeutic use Triglycerides - blood
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!